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Abstract
Context—Substantial innovation related to cancer prevention and treatment has occurred in 
recent decades. However, these innovations have often come at a significant cost. Cost-utility 
analysis provides a useful framework to assess if the benefits from innovation are worth the 
additional cost. This systematic review on published cost-utility analyses related to cancer care is 
from 1988 through 2013. Analyses were conducted in 2013–2015.
Evidence acquisition—This review analyzed data from the Tufts Medical Center Cost-
Effectiveness Analysis Registry (www.cearegistry.org), a comprehensive registry with detailed 
information on 4,339 original cost-utility analyses published in the peer-reviewed medical and 
economic literature through 2013.
Evidence synthesis—There were 721 cancer-related cost-utility analyses published from 1998 
through 2013, with roughly 12% of studies focused on primary prevention and 17% focused on 
secondary prevention. The most often studied cancers were breast cancer (29%); colorectal cancer 
(11%); and prostate cancer (8%). The median reported incremental cost-effectiveness ratios (in 
2014 U.S. dollars) were $25,000 for breast cancer, $24,000 for colorectal cancer, and $34,000 for 
prostate cancer.
Conclusions—The current evidence indicates that there are many interventions that are cost 
effective across cancer sites and levels of prevention. However, the results highlight the relatively 
small number of cancer cost-utility analyses devoted to primary prevention compared with 
secondary or tertiary prevention.
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Recent years have seen a rapid increase in new interventions in cancer prevention, diagnosis, 
and treatment.1 Although these treatments often improve survival and quality of life,1 in 
many cases they have also dramatically increased the cost of care. The National Cancer 
Institute estimates that costs of cancer care will increase by at least 27% from 2010 to 2020 
simply due to an aging population.2 The economic impact will be particularly acute in the 
Medicare program because of the program’s limited ability to control service utilization and 
the increasing number of beneficiaries due to demographic changes.3 For example, Medicare 
is legally required to cover cancer drugs that are considered a “medically accepted 
indication,” which includes not only indications approved by the U.S. Food and Drug 
Administration but also indications supported by peer-reviewed publications and listed on 
medical compendia.4 However, across Europe, economic evaluation is used extensively to 
ensure that adopted treatments provide good value for the money.5 Articles about the rising 
costs of cancer care have increasingly appeared in the popular press and medical literature.
1,5–8
 However, the situation is complicated by the fact that some cancer interventions are 
seen as “low value,”4 whereas others may provide reasonable value by conventional 
economic benchmarks despite their high costs.
Economic evaluations of healthcare interventions provide a framework for assessing the 
value of new cancer screening, diagnosis, and treatments and are used to inform 
reimbursement and coverage decisions directly or indirectly in various countries,5,9–12 
including by some payers in the U.S.13–15 Cost-effectiveness analysis (CEA) is a widely 
used economic evaluation technique to assess the value of healthcare interventions including 
cancer intervention programs.16–19 CEA describes an intervention’s impact in terms of an 
incremental cost-effectiveness ratio (ICER), which consists of its incremental costs divided 
by its incremental health benefits. To allow comparison of the relative efficiency of health-
care interventions across a spectrum of conditions such as cancer, benefits are often 
measured using quality-adjusted life-years (QALYs), and the resulting CEA referred to as a 
cost-utility analysis (CUA), with a lower ICER corresponding to greater value.20 QALYs 
capture both changes in the length and quality of life.
Application of CEA in oncology has been described in previous work,16,21,22 summarizing 
CUAs prior to 2007.8 From 2008 through 2013, the number of cancer-related CUA articles 
nearly quadrupled, with an increased focus on primary and secondary prevention. In this 
article, the authors update their previous work, concentrating on specific cancer sites, as well 
as on treatment and primary and secondary prevention.
Evidence Acquisition
The authors analyzed data from the Tufts Medical Center CEA Registry 
(www.cearegistry.org), a comprehensive registry with detailed information on 3,243 original 
CEAs published in the peer-reviewed medical and economic literature from 1988 through 
2013. Details of the CEA Registry have been described elsewhere.23 The review started with 
the first cancer-related CUA study conducted in 1988 and included all studies through 2013, 
the most recent year the CEA was updated when the study was conducted. The Tufts 
Medical Center CEA Registry contains original English-language CUA data that were 
obtained using MEDLINE, which searched for medical subject headings or text keywords 
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such as quality-adjusted, quality-adjusted life year or QALY, and cost-utility analysis. A 
total of 10,693 unique articles were identified, 4,013 of which were selected for full-text 
review based on an assessment of titles and abstracts and 4,339 included in the CEA registry 
(Figure 1). The authors excluded reviews, editorials, methodologic articles, and articles 
presenting health effects in units other than QALYs. Each article was reviewed with the aid 
of a standard data auditing form to determine its clarity, completeness, and health economic 
methodologic quality.8 The quality assessment did not assess the accuracy of the clinical or 
modeling assumptions but rather if the authors correctly reported their results, stated 
assumptions, appropriately used utility weights, and characterized uncertainty. The form was 
developed based on a variety of sources, including the “checklist” for reporting reference-
case CUAs recommended by the Panel on Cost-Effectiveness in Health and Medicine as 
well as other published guidelines.9,20 Two readers, with master’s- or doctoral-degree 
training in decision analysis and CEA, independently read and audited each article and then 
convened for a consensus audit to resolve discrepancies. The CEA Registry collected data on 
a wide variety of elements related to study sponsorship; the intervention and comparators 
under investigation; and the methods used to estimate and report costs, health effects, 
preference weights, modeling assumptions, and data limitations. The review included all 
studies that pertained to prevention, screening, and treatment of cancer, resulting in a total of 
721 articles (Figure 1).
The primary outcomes of CUAs are the costs and QALYs. The cost-utility ratio reports the 
incremental change of the new intervention compared to the status quo. Because the CUAs 
in this review were conducted in numerous countries using different currencies for a period 
of >20 years, all non-U.S. currencies were converted into U.S. dollars using the appropriate 
foreign exchange factor for the relevant year, and all ratios inflated to 2014 U.S. dollars 
using the Consumer Price Index obtained from the Bureau of Labor Statistics available from 
www.bls.gov/cpi/data.htm.
The authors grouped studies pertaining to cancer into 18 broad subcategories by the type of 
cancer treated or prevented: breast; colorectal; cervix; prostate; lung; melanoma; 
hematologic cancers; gastrointestinal and hepatocellular; ovarian; brain; bladder; kidney; 
head and neck (the nose, sinuses, lips, oral cavity, salivary glands, throat, or larynx)24; 
uterus; pancreas; stomach; esophagus; and other cancers. Because some CUAs compared 
several interventions and included scenarios specific to patient subgroups or settings, a 
single study may have contributed more than one cost-utility ratio. In these situations, the 
ratio was weighted inversely according to the number of ratios reported in the article. That 
is, each ratio was assigned a statistical weight of 1/n, where n was the number of ratios 
reported in an article.
The reported ratios were classified as most cost effective with values <$50,000, cost 
effective as $50,000–$100,000, and least cost effective as >$100,000 per QALY using 
willingness-to-pay threshold levels sometimes used by health economists. These threshold 
levels, though somewhat arbitrary, are based on conventions sometimes used in the U.S. to 
determine the cost effectiveness of an intervention.20 Additionally, some ratios report cost 
savings and increasing health, which health economists refer to as dominant and the authors 
report as “cost saving,” and other ratios report decreased health with increasing cost, which 
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health economists refer to as dominated and the authors report as “decreased health, 
increased costs.” Chi-square tests were used to determine if categorical variables were 
statistically significant. Analyses were conducted in 2013–2015.
Interventions were classified as primary, secondary, or tertiary prevention.25 Primary 
prevention is defined as the avoidance of the onset of disease by behavior modification or 
treatment. Examples of primary prevention could include chemoprevention for breast cancer, 
immunization, health education, and promotion of improved nutrition. Secondary prevention 
is defined as the avoidance or alleviation of disease by early detection and appropriate 
management. Examples include early clinical services and population screening to identify 
disease in asymptomatic people to enable timely treatment. Tertiary prevention is defined as 
being the treatment of an active disease and may include treatment to reduce complications 
and progression of established disease, for example, chemotherapy, surgical removal of a 
tumor, and radiation therapy.
Evidence Synthesis
The authors identified 721 original cancer-related CUAs in the CEA Registry. Appendix A 
(available online) provides summaries of the articles. The annual average number of cancer-
related CUAs has increased markedly over time (Appendix Figure 1, available online). 
Moreover, the proportion of studies focused on primary and secondary prevention has 
increased from an average of four studies per year between 1998 and 2006 to 20 studies per 
year between 2007 and 2011 to 100 studies per year in 2012 and 2013. The top three studied 
diseases were breast cancer (29% of studies); colorectal cancer (11%); and prostate cancer 
(8%) (Table 2). Most studies pertained to the U.S. (40% of studies), followed by the United 
Kingdom (14%); Canada (9%); and the Netherlands (6%) (Table 1). The majority examined 
interventions for tertiary prevention (i.e., chemotherapy and post-diagnosis interventions, 
71%), followed by secondary prevention (i.e., screening, 17%) and primary prevention (i.e., 
vaccination, 12%). Most published CUAs focused on pharmaceutical interventions (51%), 
followed by screening strategies (16%) and medical procedures (11%). Approximately 30% 
of studies were funded by pharmaceutical or device companies; 49% were funded by non-
industry sources (i.e., government, foundations, and healthcare organizations); and 21% did 
not disclose their funding source (Table 1).
Overall, the 721 analyses presented 2,053 ICERs (of which 52% CUAs presented more than 
one ratio). The median reported cost-effectiveness ratios (in 2014 USD) for all cancer-
related CUAs were $29,000, which is not significantly different between prevention 
categories (p=0.11). The median reported cost-effectiveness ratios (in 2014 USD) were 
$25,000 for breast cancer, $24,000 for colorectal cancer, $18,000 for cervical cancer, 
$37,000 for lung cancer, and $46,000 for melanoma (Table 2).
The reported cost-effectiveness ratios for screening interventions were generally in ranges 
conventionally thought of as most cost effective (<$50,000), except for prostate and kidney 
cancer, which was still found to be cost effective ($50,000–$100,000) (Appendix Table 1). 
The search identified 118 studies focused on screening interventions. For cancers 
recommended for screening by the U.S. Preventive Services Task Force at the time these 
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data were collected, the median ICER was $22,000 for breast, $15,000 for colorectal, and 
$28,000 for cervical. On the other hand, for cancers not recommended for screening at the 
time these data were collected, the median ICER was $30,000 for lung and $46,000 for 
melanoma. Few studies have examined the cost effectiveness of screening for melanoma.
The median ICER for interventions on primary cancer prevention programs was $23,000 
(Table 2). For specific cancer sites, the median reported cost-effectiveness ratios were 
$48,000 for breast, cost saving for colorectal, $16,000 for cervical, $17,000 for lung, 
$120,000 for prostate, and $27,000 for melanoma. The distribution of ICERs by cancer site 
is presented in Table 3.
When the distribution of ICERs across all studies was assessed, 69% of ratios were <
$50,000 or cost saving, 13% of ratios were between $50,000 and $100,000, and 21% of 
ratios were >$100,000 or decreased health and increased costs (Table 3). When the 
distribution of ICERs among primary prevention studies (Table 3) was examined, 78% were 
<$50,000 or cost saving, 12% were between $50,000 and $100,000, and 11% of ratios were 
>100,000 or decreased health and increased costs (Table 3). When looking at specific cancer 
sites among studies focused on primary prevention, the distribution of ICERs was similar 
across diseases, with the exception of prostate cancer (five studies), where at least half of the 
studies reported ICERs >$100,000.
There were more CUAs focused on tertiary (n=511) than secondary prevention (n=120) 
(Table 2). Though median ICERs were somewhat higher for secondary ($34,000) than for 
tertiary prevention ($29,000) (Table 2), the distribution was similar (Table 3), with 63% of 
studies reporting ICERs <$50,000 or cost saving, 31% reporting ICERs >$50,000, and 5%–
6% reporting decreased health and increased costs.
Discussion
The authors systematically reviewed all published cancer-related CUAs and updated their 
previous review. Since 2007, the number of cancer-related CUAs has almost quadrupled. 
This is likely due to payers worldwide (e.g., the National Institute for Health and Care 
Excellence in the United Kingdom) using data from economic evaluations to inform and 
support reimbursement decisions.5,9,11,12 However, the focus of studies is similar to prior 
work.8 Consistent with cancer-related CUAs published before 2008, this study found that 
researchers have devoted relatively little attention, as measured by publications, to the cost 
effectiveness of primary prevention compared with secondary or tertiary prevention.8 As 
seen in work published before 2008, the majority of primary prevention studies were 
focused on cervical or breast cancer. For secondary prevention, there have been many CUAs 
focused on breast, colorectal, and cervical cancer, which is perhaps not surprising as these 
are cancer sites where screening is recommended. By contrast, few CUAs have examined 
screening for melanoma or lung cancer, areas in which screening are not recommended 
during our study period. However, in recent years, there has been movement to recommend 
low-dose computed tomography screening to detect lung cancer for specified group of 
individuals at high risk.23 CUA studies published since 2013 on lung cancer have been 
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mixed, and have shown that the cost effectiveness of lung cancer screening is very sensitive 
to the assumptions on the effectiveness of screening.24–26
Numerous CUAs have examined tertiary prevention. Interestingly, the median and 
distribution of cancer cost-effectiveness ratios are similar to those found in other fields of 
health care.26–29 Despite the fact that this updated review of cancer-related CUAs included 
many new expensive cancer drugs (e.g., cetuximab, bevacizumab, sunitinib, sorafenib), the 
distribution of ICERs has remained relatively constant over time. However, the cost-
effectiveness literature may have been subject to publication bias in the sense that 
researchers and funders may selectively conduct cost-effectiveness studies and under-report 
unfavorable cost-effectiveness results.27
Limitations
This study has several limitations. First, it excluded CEAs that used measures of health 
outside of the QALY metric (e.g., cost per life-year gained or cost per 1 year of progression-
free survival). Second, it only included English-language peer-reviewed publications 
indexed in MEDLINE. For example, health technology assessment reports, created by 
governmental bodies such as the National Institute for Clinical Excellence in the United 
Kingdom or other health technology assessment agencies, were excluded. However, the 
findings in some of these reports are complementary to the reviewed studies.5,9,11,12 Third, 
this study did not assess the merits of clinical or modeling assumptions included in analyses 
or the quality of the data collected in studies conducted alongside clinical trials. Fourth, 
environmental, system, and policy interventions were not included in the reviewed studies. 
Fifth, this study only goes through 2013 and does not capture more recently published 
studies.
A final point worth emphasizing is that policy-makers using cost-utility information should 
examine carefully the individual studies and their interventions, comparators, and target 
populations when making decisions. The results presented here are summary data that 
provide a portrait of the literature to date. However, individual studies will investigate very 
different contexts (e.g., a colorectal cancer screening finding may be based on a comparison 
of colonoscopy versus fecal occult blood testing, whereas a treatment for stomach cancer 
result might be compared with diet and nutrition counseling). In recognition of the 
importance of economic evaluation, some countries have begun to use outcomes of 
economic analyses to inform coverage decisions, which has in turn contributed to 
restrictions in patients’ access to new and expensive drugs.9,10,12,30,31 Some have also 
acknowledged the unique circumstances of end-of-life care and have created mechanisms for 
coverage of cancer drugs or more flexible reimbursement criteria.9,10,12 For example, in 
Canada or the United Kingdom, cancer drugs have been adopted at higher than average 
thresholds of cost effectiveness.10,12 However, these higher thresholds appear to apply only 
to drugs and not to cancer screening.
Conclusions
In summary, the current evidence indicates that there are many interventions that are cost 
effective across cancer sites and stages of prevention. However, the results highlight the 
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relatively small number of cancer CUAs devoted to primary prevention compared with 
secondary or tertiary prevention.
Supplementary Material
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Figure 1. 
PRISMA article identification and selection process.
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Table 1
Characteristics of the Cancer Cost-Utility Analysis Literature
Characteristic Number of studies (total N=721) Percentage of studies, %
Country of study
 U.S. 287 40
 United Kingdom 98 14
 Canada 67 9
 Netherlands 41 6
 Australia 19 3
 Italy 19 3
 Sweden 18 2
 France 17 2
 China 15 2
 Other 140 19
Intervention
 Pharmaceuticals 367 51
 Screening 118 16
 Medical procedure 82 11
 Diagnostic 53 7
 Other 62 9
 Surgery 39 6
Level of prevention
 Primary 89 12
 Secondary 121 17
 Tertiary 511 71
Study sponsorship
 Non-industry 349 49
 Industry 146 30
 Not specified 226 21
Note: Intervention categories consist of the following: Pharmaceuticals = any drug or biotech product used for medical treatment or prevention; 
Screening = refers to measures that detect disease (or test for risk factors) before it is symptomatic; Medical Procedure = non-surgical, non-
diagnostic procedures; Diagnostic = a method used to determine if and what type of disease is present; Surgery = invasive, cutting involved (e.g., 
transplantation, although bone marrow transplantation would be a medical procedure, appendectomy).
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